Fexofenadine, a Putative<i>In Vivo</i>P‐glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients
2017 · Clinical Pharmacology & Therapeutics · 11 citations
https://doi.org/10.1002/cpt.718
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
911
Citations
14
h-index
17
i10-index
Thomas Vanhove is an academic researcher from Centre Hospitalier de Luxembourg. The author has contributed to research in topics: Renal Transplantation Outcomes and Treatments & Pharmacological Effects and Toxicity Studies & Organ Transplantation Techniques and Outcomes. The author has an h-index of 14, co-authored 26 publications.
ORCID: 0000-0001-5712-6294https://doi.org/10.1002/cpt.718
https://doi.org/10.1016/j.transproceed.2025.10.023
Click to start Chat